Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

FDA Drug Recalls

18,003 recalls, newest first

Class I · High risk

BD ChloraPrep Hi-Lite Orange 2% w/v chlorhexidine gluconate

Non-sterility: Product is being recalled to climatic Zone IV regions of the world where at the labeled storage conditions of 30*C/75% Relative Humidity for more than 6 months, there is the potential for growth of Aspergillus penicillioides, a type of fungus, resulting in a breach of the package integrity.

Terminated Sterility / contamination CareFusion 213, LLC NDC 54365-400-33 D-0268-2021
Class I · High risk

ChloraPrep One-Step 2% w/v chlorhexidine gluconate

Microbial Contamination of Non-Sterile Product: Product is being recalled to climatic Zone IV regions of the world where at the labeled storage conditions of 30*C/75% Relative Humidity for more than 6 months, there is the potential for growth of Aspergillus penicillioides, a type of fungus, resulting in a breach of the package integrity.

Terminated Microbial contamination CareFusion 213, LLC D-0267-2021
Class I · High risk

ChloraPrep With Tint 2% w/v chlorhexidine gluconate

Microbial Contamination of Non-Sterile Products:Product is being recalled to climatic Zone IV regions of the world where at the labeled storage conditions of 30*C/75% Relative Humidity for more than 6 months, there is the potential for growth of Aspergillus penicillioides, a type of fungus, resulting in a breach of the package integrity.

Terminated Microbial contamination CareFusion 213, LLC D-0266-2021
Class I · High risk

BD ChloraPrep Clear

Non-sterility: Product is being recalled to climatic Zone IV regions of the world where at the labeled storage conditions of 30*C/75% Relative Humidity for more than 6 months, there is the potential for growth of Aspergillus penicillioides, a type of fungus, resulting in a breach of the package integrity.

Terminated Sterility / contamination CareFusion 213, LLC NDC 54365-400-32 D-0265-2021
Class III · Low risk

Clonazepam Orally Disintegrating Tablets

Cross contamination with other products - OOS discovered during routine stability testing for highest unknown impurity later identified as clozapine

Terminated Cross-contamination Sun Pharmaceutical Industries INC NDC 57664-783-86 D-1445-2020
Class II · Moderate risk

Vardenafil 20 mg Troche

Lack of Processing Controls (lack of assurance of conformity to specifications).

Terminated cGMP deviation MasterPharm LLC D-1442-2020
Class II · Moderate risk

Tadalafil 7 mg Capsule

Lack of Processing Controls (lack of assurance of conformity to specifications).

Terminated cGMP deviation MasterPharm LLC D-1440-2020
Class II · Moderate risk

Tadalafil 3 mg Capsule

Lack of Processing Controls (lack of assurance of conformity to specifications).

Terminated cGMP deviation MasterPharm LLC D-1439-2020
Class II · Moderate risk

Tadalafil 26 mg Capsule

Lack of Processing Controls (lack of assurance of conformity to specifications).

Terminated cGMP deviation MasterPharm LLC D-1438-2020
Class II · Moderate risk

Tadalafil 18 mg Capsule

Lack of Processing Controls (lack of assurance of conformity to specifications).

Terminated cGMP deviation MasterPharm LLC D-1437-2020
Class II · Moderate risk

Tadalafil 12 mg Capsule

Lack of Processing Controls (lack of assurance of conformity to specifications).

Terminated cGMP deviation MasterPharm LLC D-1436-2020
Class II · Moderate risk

Sildenafil 50 mg Troche

Lack of Processing Controls (lack of assurance of conformity to specifications).

Terminated cGMP deviation MasterPharm LLC D-1435-2020

Recalls by year